Current Report · Items 2.02, 9.01 · 8-K

NeuroOne Medical Technologies Corporation

NMTCNASDAQEQUITYCurrent

Results of Operations and Financial Condition

Filed Feb 17, 2026Accepted Feb 17, 2026, 8:00 AM ESTCIK 1500198Accession 0001213900-26-016912

Company context

NeuroOne Medical Technologies Corporation is a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders. NeuroOne markets a minimally invasive and high-definition/high-precision electrode technology platform with four FDA-cleared product families: Evo® Cortical Electrodes, Evo® sEEG Electrodes, OneRF® Ablation System (for brain), and OneRF® Trigeminal Nerve Ablation System. These solutions offer the potential to reduce the number of hospitalizations and surgical procedures, lower costs, and improve patient outcomes by offering diagnostic and therapeutic functions. The Company is engaged in research and development for drug delivery, basivertebral nerve ablation and spinal cord stimulation programs. For more information, visit nmtc1.com.

Current securities

NMTCNASDAQ · EQUITY · Current

Recent company filings

Disclosure sections

Items 2.02, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 2.02Item 2.02 - Results of Operations

Item 2.02 Results of Operations and Financial Condition. On February 17, 2026, NeuroOne Medical Technologies Corporation (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended December 31, 2025. A copy of this press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K (this “Current Report”) and is incorporated herein by reference. In accordance with General Instruction B.2. of Form 8-K, the information contained in Item 2.02 of this Current Report, including Exhibit 99.1 hereto, is furnished pursuant to Item 2.02 and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any of the Company’s filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any incorporation language in such a filing, except as expressly set forth by specific reference in such a filing.

Filed exhibits (1)

EX-99.1 (by filename) ea027713101ex99-1_neuroone.htm

EX-99.1 2 ea027713101ex99-1_neuroone.htm PRESS RELEASE, DATED FEBRUARY 17, 2026 Exhibit 99.1 NeuroOne Reports Fiscal Q1 2026 Financial Results; Expects Product Revenue of At Least $10.5 Million in Fiscal Year 2026 Nearly 50% of all Ablations Since OneRF ® Ablation System Product Launch in 2024 were Performed in Fiscal Q1 2026, Showing Growing Adoption Following FDA 510(k) Clearance, Successfully Completed Nine Trigeminal Neuralgia Cases to Date, with All Patients Reportedly Pain Free* Management to Host Conference Call Today at 8:30 a.m. Eastern Time EDEN PRAIRIE, Minn., February 17, 2026 -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company dedicated to transforming the surgical diagnosis and treatment of neurological disorders, has reported financial results and a business update for the first quarter of fiscal year 2026 ended December 31, 2025. Company Highlights The Company expects an increase in product revenue to at least $10.5 million in fiscal year 2026, representing an increase of at least 17% when compared to product revenue of $9.1 million in fiscal year 2025. Successfully received FD…

Open exhibit ↗

Get the free weekly BCS email.